Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males

Highlights • qHPV efficacy against EGL and intra-anal disease related to HPV in men has been demonstrated. • We examine efficacy against disease due to 10 additional non-vaccine HPV types. • Vaccinating men against HPV 6/11/16/18 protects against most vaccine HPV-type related anogenital disease. • S...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2013-08, Vol.31 (37), p.3849-3855
Main Authors: Goldstone, Stephen E, Jessen, Heiko, Palefsky, Joel M, Giuliano, Anna R, Moreira, Edson D, Vardas, Eftyhia, Aranda, Carlos, Hillman, Richard J, Ferris, Daron G, Coutlee, Francois, Marshall, J. Brooke, Vuocolo, Scott, Haupt, Richard M, Guris, Dalya, Garner, Elizabeth
Format: Article
Language:English
Subjects:
Adolescent
Adult
Allergy and Immunology
Anal Canal - pathology
Anal Canal - virology
Anogenital
Anus Neoplasms - epidemiology
Anus Neoplasms - virology
Applied microbiology
Biological and medical sciences
Cervical cancer
Fundamental and applied biological sciences. Psychology
Genital Neoplasms, Male - pathology
Genital Neoplasms, Male - prevention & control
Genital Neoplasms, Male - virology
HPV
Human papillomavirus
Human papillomavirus 11 - pathogenicity
Human papillomavirus 16 - pathogenicity
Human papillomavirus 18 - pathogenicity
Human papillomavirus 6 - pathogenicity
Humans
Laboratories
Male
Males
men
Men who have sex with men
Microbiology
Papillomavirus Infections - epidemiology
Papillomavirus Infections - prevention & control
Papillomavirus Infections - virology
Papillomavirus Vaccines - therapeutic use
Treatment Outcome
vaccination
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Young
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • qHPV efficacy against EGL and intra-anal disease related to HPV in men has been demonstrated. • We examine efficacy against disease due to 10 additional non-vaccine HPV types. • Vaccinating men against HPV 6/11/16/18 protects against most vaccine HPV-type related anogenital disease. • Significant efficacy against disease due to non-vaccine HPV types was not seen. • No evidence of increased disease caused by non-vaccine types was evident.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2013.06.057